Health standards and regulations
Quality and governance
The safety of each and every one of our patients is our top priority. This is why we have a quality and governance framework in place to provide assurance on our compliance with standards and our statutory obligations.
Our systematic approach to continuous quality improvement ensures that the care we provide is constantly enhanced, while also providing a clearly-defined risk and escalation process.
The processes we have established are carried out every single day of the year, with the resulting data being closely reviewed and collated by our quality and governance experts. Everything we learn from them is escalated throughout our business, right up to our leadership team. We also share learnings with every Sciensus employee, from head office and helpline teams to the nurses and delivery drivers who visit our patients.
Working with regulators
We work closely with regulators to ensure standards are met and we continue to deliver a consistently outstanding level of care.
Each of these regulators rightly expects us to provide a well-led service that offers safe and effective care to the patients we care for. They review this by working closely with us throughout the year and carrying out regular inspections.
We also take a proactive approach, constantly monitoring ourselves against the standards our regulators set, and using our corporate governance structure to help our teams exceed expectations, time and time again.
We are registered with the General Pharmacy Council for our pharmacy activity and our medication logistic network complies with Good Distribution Practice regulations from the Medicines and Healthcare products Regulatory Agency (MHRA).
As the leading provider of out-of-hospital care in the UK, we’re also regulated by a number of health and social care bodies, including the Care Quality Commission (England), the Regulatory Quality Improvement Authority (Northern Ireland) and the Care Inspectorate for Scotland.
Read more on…
Blogs/Articles
Four considerations before collecting real-world data in your EAP
Expanded access programs (EAPs) for rare disease medications present a valuable opportunity for biotechs to collect real-world data (RWD). In…
Blogs/Articles
The increasing importance of real-world data for the EMA
Over recent years, real-world data (RWD) has become a critical element of the development and commercialization of medications. RWD includes…
Blogs/Articles
Six steps for a successful Expanded Access Program in Europe
For biotech companies seeking to bring a new rare disease treatment to market in Europe, there can be many obstacles…